Delta Air Lines revives Pittsburgh-Orlando route with seasonal weekly flights starting December 2025
It will be the first time Delta (NYSE: DAL) will serve the two airports since 2019.
The new flights will be on Delta's regional carrier, Republic Airways, and on the Embraer E175 regional jets that carry 75 passengers. They will begin Saturday, Dec. 20, and last through April 11, 2026. The flight leaves Pittsburgh International Airport at 9:50 a.m. and arrives at Orlando International Airport at 12:20 p.m. The return flight leaves Orlando at 1:05 p.m. and arrives in Pittsburgh at 3:25 p.m., according to the Delta website.
Delta started selling tickets for the flights Saturday.
Click here to read more from our partners at the Pittsburgh Business Times.
Download the FREE WPXI News app for breaking news alerts.
Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever
Key Points Johnson & Johnson has a historically high yield, and it is a Dividend King. Medtronic is two years shy of Dividend King status and has a historically high yield. Merck's dividend has grown steadily, though not annually, for decades. 10 stocks we like better than Johnson & Johnson › Healthcare stocks aren't exactly known for offering large yields, with the average healthcare stock at just 1.8% or so. You can do better than that and get reliable dividend stocks while you are at it. All you need to do is buy Johnson & Johnson (NYSE: JNJ), Medtronic (NYSE: MDT), and Merck (NYSE: MRK), and then hold them forever. Here's what you need to know. 1. Johnson & Johnson is a Dividend King When it comes to reliable dividend stocks, the highest honor that is bestowed on a company is the rank of Dividend King. A company has to increase its dividend annually for five decades to earn that title. Johnson & Johnson's dividend streak is up to 63 years, which is the longest streak of any healthcare company. The dividend yield is an attractive 3.1%. That yield is not only well above the healthcare average, it's also toward the high end of Johnson & Johnson's historical yield range. Historically speaking, the stock looks like it is on sale despite what is a very impressive and well-run business. The company is an industry-leading pharmaceutical and medical device maker. That said, there's a bit of uncertainty here today. Johnson & Johnson is facing a fairly large class action lawsuit around talcum powder it sold. It will likely survive through this, but the overhang of the suit could be a drag for a while. If that doesn't bother you, though, jump in. One thousand dollars will get you around five shares of Johnson & Johnson stock. 2. Medtronic is two years shy of being a Dividend King Medtronic has increased its dividend annually for 48 consecutive years. That's not as good as the streak Johnson & Johnson has built, but it is still pretty darn impressive. Medtronic is focused exclusively on medical devices, and it has a dividend yield of roughly 3.1% today. Like Johnson & Johnson, Medtronic is one of the largest players in the sectors it serves. Medtronic's dividend yield also happens to be historically high right now. Unlike with Johnson & Johnson, however, the problems here don't involve a large class action lawsuit. Medtronic's growth has slowed down, thanks at least in part to a period in which few new products were being introduced. Management is working to fix the issue. For starters, new products are again starting to come to market (innovation is lumpy, so this isn't shocking). The company is also attempting to refocus around its most desirable businesses. The end result is likely to be a more profitable and faster-growing company. But for now, Wall Street remains in a "show me" mood, which is an opportunity for buy-and-hold dividend investors to jump aboard an industry-leading medical device maker while it has a historically attractive dividend yield. A $1K investment will net you roughly 10 shares of Medtronic. 3. Merck's dividend record is good, but not kingly Merck is one of the largest pharmaceutical companies on the planet. As noted, innovation is lumpy, and that's particularly true when it comes to drugs. Add in the fact that drug patents only allow exclusivity for so long, and there's always a cliff somewhere down the line for drugmakers with blockbuster products. This is the nature of Merck's business, and there's nothing that can be done about it. Sometimes it just takes a little bit longer than hoped to find a new drug to replace the ones that are losing patent protections. What's actually impressive is that, despite the ups and downs, Merck has managed to keep its dividend growing over time. That hasn't happened every single year -- there have been some lengthy periods when the dividend was static. But generally higher over time is still quite attractive when you add it to a historically high 3.9% or so dividend yield. There's no telling when Merck will find its next blockbuster. It may develop it in-house, or it might buy a company to acquire an attractive drug. But history suggests that buying and holding this giant drugmaker has been a win for dividend lovers with a holding period of "forever." Investing $1,000 here will allow you to buy about 11 shares of Merck. What are you really buying? Johnson & Johnson, Medtronic, and Merck are all high-yield healthcare stocks with strong dividend records. But that's not really all you're buying here. The truth is, healthcare is a very complex sector, and these three industry giants are standout businesses. You may not be expert enough in healthcare to keep up with the innovation in the industry, but these three companies are experts. In other words, you're getting well-run businesses that are doing the heavy lifting in the healthcare sector so you don't have to be an expert. Along with that, you're getting attractive dividend yields backed by solid dividend histories. Should you buy stock in Johnson & Johnson right now? Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Merck. The Motley Fool recommends Johnson & Johnson and Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever was originally published by The Motley Fool
Yahoo
2 minutes ago
- Yahoo
UnitedHealth Stock Is Having Its Worst Year Since 2008. Can It Recover?
Key Points It isn't typical for UnitedHealth stock to finish a year lower than it started, let alone be down more than 40% as it is right now. Rising costs and uncertainty around healthcare reform are just a couple of the issues plaguing the stock. It's trading around multiyear lows, however, and is arguably a cheap buy. 10 stocks we like better than UnitedHealth Group › For years UnitedHealth Group (NYSE: UNH) has normally been a reliable dividend stock. But an abysmal start to 2025 has wiped out many of the gains that investors have achieved in recent years, with its five-year return now in negative territory. Year to date, the stock has fallen by nearly 45%, which is by no means normal for the healthcare stock. In fact, this is the worst it has performed since the Great Recession, when it tumbled by more than 54% in 2008. The big questions many investors are likely asking today are: Can it recover? Or is there more of a downfall to come for this once seemingly unstoppable stock? Big declines aren't the norm for UnitedHealth The past few years haven't been all that great for UnitedHealth, but by and large, this has been a fairly strong stock to own. It has typically outperformed the market. And outside of 2024 -- when it was down 4% -- the last time it finished a year in the red was (as noted) back in 2008, when the U.S. economy was in the midst of the Great Recession and the stock lost more than half of its value. Not only has UnitedHealth normally been a safe stock, it's also been a tremendous growth stock. Consider that if you invested $10,000 into its shares at the end of 2003, then 20 years later your investment would have been worth $181,000. But if you hung on until now, that investment would have fallen to a value of $101,000. While that's still a good return, it spotlights just how significant the decline has been this year, for a stock that's typically known for being a solid long-term investment. Still, the past doesn't predict the future. Why the company might face a tough road ahead The problem with UnitedHealth right now is that it's facing many challenges. Medical costs are up, and there's a lot of uncertainty in healthcare as the federal government looks to cut costs. Meanwhile, the Department of Justice is reportedly looking into UnitedHealth's billing practices. The danger is that the company may face financial repercussions and other headwinds, such as having to change its practices -- or at the very least, incurring higher-than-typical costs due to greater utilization rates. The latter, however, may be a shorter-term trend. Either way, this is a business known for consistently growing its operations, and that may not be a sure thing anymore. While UnitedHealth generated a healthy profit of more than $14.4 billion on revenue of $400.3 billion in 2024, investor concerns about long-term growth appear to be weighing on the stock. In May, the company suspended its outlook for the year; it also announced a change in CEO, with Andrew Witty stepping down for personal reasons and former CEO Stephen Hemsley taking over. Should you buy UnitedHealth stock today? While UnitedHealth stock has done well in previous years, that doesn't mean that it's a surefire bet to rebound soon. The good news is that it still has solid fundamentals. Since it's a key health insurer in the U.S., I'd be hesitant to count it out in the long run. There's some near-term risk and even some long-term uncertainty about how all the changes in the healthcare industry might pan out. But the stock is trading at levels it hasn't been at since 2020, and its valuation is just 12 times its trailing earnings. I think that gives it a good enough margin of safety at its current price, and that buying it today might prove to be a solid move. As long as you're willing to be patient, this can be a good stock to buy and hold. Should you buy stock in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. UnitedHealth Stock Is Having Its Worst Year Since 2008. Can It Recover? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 minutes ago
- Business Wire
CenterPoint Energy, Inc. Announces Pricing of Offering of $900 Million of 3.00% Convertible Senior Notes Due 2028
HOUSTON--(BUSINESS WIRE)--CenterPoint Energy, Inc. (NYSE: CNP) or 'CenterPoint' today announced the pricing of its offering of $900 million aggregate principal amount of its 3.00% Convertible Senior Notes due 2028 (the 'convertible notes') in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the 'Securities Act'). CenterPoint also granted the initial purchasers of the convertible notes the option to purchase up to an additional $100 million aggregate principal amount of convertible notes for settlement within a 13-day period beginning on, and including, the date on which the convertible notes are first issued. The sale of the convertible notes is expected to close on July 31, 2025. The convertible notes will be senior, unsecured obligations of CenterPoint. The convertible notes will mature on August 1, 2028, unless earlier converted or repurchased. The convertible notes will bear interest at a rate of 3.00% per year, payable semiannually in arrears on February 1 and August 1 of each year, beginning on February 1, 2026. Prior to May 1, 2028, the convertible notes will be convertible only upon the occurrence of certain events and during certain periods. Thereafter, the convertible notes will be convertible by holders at any time in whole or in part until the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, CenterPoint will pay cash up to the aggregate principal amount of the convertible notes to be converted and pay or deliver, as the case may be, cash, shares of CenterPoint's common stock, par value $0.01 ('common stock'), or a combination of cash and shares of common stock, at CenterPoint's election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the convertible notes being converted. CenterPoint may not redeem the convertible notes prior to the maturity date. The initial conversion rate for the convertible notes will be 21.4477 shares of common stock per $1,000 principal amount of convertible notes (equivalent to an initial conversion price of approximately $46.63 per share of the common stock). The conversion rate and the corresponding conversion price will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. CenterPoint expects that the net proceeds from the offering of the convertible notes will be approximately $888.1 million (or approximately $986.8 million if the initial purchasers exercise their option to purchase additional convertible notes in full), after deducting the initial purchasers' discounts and commissions and offering expenses payable by CenterPoint. CenterPoint intends to use the net proceeds from this offering for general corporate purposes, including the repayment of a portion of its outstanding commercial paper and other debt. The convertible notes and any shares of common stock issuable upon conversion of the convertible notes have been offered and sold only to persons reasonably believed to be qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act. The offer and sale of the convertible notes and any shares of common stock issuable upon conversion of the convertible notes have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any jurisdiction in which the offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any jurisdiction. About CenterPoint As the only investor-owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Indiana, Minnesota, Ohio and Texas. As of June 30, 2025, the company owned approximately $44 billion in assets. With approximately 8,300 employees, CenterPoint and its predecessor companies have been in business for more than 150 years. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'potential,' 'predict,' 'projection,' 'should,' 'target,' 'will,' 'would' or other similar words are intended to identify forward-looking statements. Any statements in this press release regarding future events that are not historical facts are forward-looking statements. These forward-looking statements, which include statements regarding CenterPoint's expectations regarding the closing of the sale of the convertible notes and the use of the net proceeds from the sale, are based upon assumptions of management which are believed to be reasonable at the time made and are subject to significant risks and uncertainties. Actual events and results may differ materially from those expressed or implied by these forward-looking statements. CenterPoint cannot be sure that it will close the sale of the convertible notes or, if it does, on what terms the sale will be closed. Each forward-looking statement contained in this press release speaks only as of the date of this release, and CenterPoint does not assume any duty to update or revise forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by the provided forward-looking information include risks and uncertainties relating to: (1) actions by credit rating agencies, including any potential downgrades to credit ratings; (2) financial market conditions; (3) general economic conditions; (4) the timing and impact of future regulatory, executive and legislative decisions and actions; and (5) other factors, risks and uncertainties discussed in CenterPoint's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and CenterPoint's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025 and other reports CenterPoint or its subsidiaries may file from time to time with the Securities and Exchange Commission ('SEC'). You are cautioned not to place undue reliance on CenterPoint's forward-looking statements. Investors and others should note that CenterPoint may announce material information using SEC filings and the Investor Relations page of its website, including press releases, public conference calls, webcasts and other investor information. In the future, CenterPoint expects to continue to use these channels to distribute material information about CenterPoint and to communicate important information about CenterPoint, key personnel, corporate initiatives, regulatory updates, and other matters. Information that CenterPoint posts on its website could be deemed material; therefore, investors are encouraged to review the information posted on the Investor Relations page of CenterPoint's website.
